Extended spectrum β-lactamases mediated bacterial resistance: Implications for the intensivist;Résistance bactérienne par β-lactamases à spectre étendu : implications pour le réanimateur

Reanimation

Volumn 15, Issue 3, 2006, Pages 205-213

  Rodriguez Villalobos, H ^a   Struelens, M J ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Enterobacteriaceae; ESBL; Nosocomial infection; Prevention, Drug therapy

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CEPHAMYCIN; CLAVULANIC ACID; IMIPENEM; MEROPENEM; METICILLIN; OXACILLIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM DETECTION; ENTEROBACTERIACEAE; GENETIC VARIABILITY; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; INTENSIVE CARE UNIT; PREVALENCE; PSEUDOMONAS; RISK FACTOR; SHORT SURVEY;

EID: 33646755553     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2006.03.006     Document Type: Short Survey

References (73)

1. Livermore D.M. β-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8 (1995) 557-584
2. st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14 (2001) 933-951
3. Jacoby G.A., and Munoz-Price L.S. The new β-lactamases. N. Engl. J. Med. 352 (2005) 380-391
4. Paterson D.L., and Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18 (2005) 657-686
5. Nordmann P., and Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8 (2002) 321-331
6. Thomson K.S., and Moland E.S. Version 2000: the new β-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect. 2 (2000) 1225-1235
7. Naas T., and Nordmann P. OXA-type β-lactamases. Curr. Pharm. Des. 5 (2005) 865-879
8. Livermore D.M., and Woodford N. Carbapenemases: a problem in waiting?. Curr. Opin. Microbiol. 3 (2000) 489-495
9. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48 (2004) 1-14
10. Walther-Rasmussen J., and Hoiby N. Cefotaximases (CTX-Mases), an expanding family of extended-spectrum β-lactamases. Can. J. Microbiol. 50 (2004) 137-165
11. Poirel L., Menuteau O., Agoli N., Cattoen C., and Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J. Clin. Microbiol. 41 (2003) 3542-3547
12. Poirel L., Le Thomas I., Naas T., Karim A., and Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44 (2000) 622-632
13. Weldhagen G.F., Poirel L., and Nordmann P. Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob. Agents Chemother. 47 (2003) 2385-2392
14. Pagani L., Mantengoli E., Migliavacca R., Nucleo E., Pollini S., Spalla M., et al. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase in northern Italy. J. Clin. Microbiol. 42 (2004) 2523-2529
15. De Champs C., Poirel L., Bonnet R., Sirot D., Chanal C., Sirot J., et al. Prospective survey of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob. Agents Chemother. 46 (2002) 3031-3034
16. Philippon A., Arlet G., and Jacoby G.A. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46 (2002) 1-11
17. Hanson N.D. AmpC β-lactamases: what do we need to know for the future?. J. Antimicrob. Chemother. 52 (2003) 2-4
18. Livermore D.M., and Brown D.F. Detection of β-lactamase-mediated resistance. J. Antimicrob. Chemother. 48 Suppl 1 (2001) 59-64
19. Sanders C.C., Barry A.L., Washington J.A., Shubert C., Moland E.S., Traczewski M.M., et al. Detection of extended-spectrum-β-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL-test. J. Clin. Microbiol. 34 (1996) 2997-3001
20. Livermore D.M., Struelens M., Amorim J., Baquero F., Bille J., Canton R., et al. Multicentre evaluation of the Vitek 2 advanced expert system for interpretive reading of antimicrobial resistance tests. J. Antimicrob. Chemother. 49 (2002) 289-300
21. Sturenburg E., Sobottka I., Feucht H.H., Mack D., and Laufs R. Comparison of BDPhoenix and Vitek 2 automated antimicrobial susceptibility test systems for extended-spectrum β-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagn. Microbiol. Infect. Dis. 45 (2003) 29-34
22. Wu T.L., Siu L.K., Su L.H., Lauderdale T.L., Lin F.M., Leu H.S., et al. Outer membrane protein change combined with co-existing TEM-1 and SHV-1 β-lactamases lead to false identification of ESBL-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 47 (2001) 755-761
23. Queenan A.M., Foleno B., Gownley C., Wira E., and Bush K. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J. Clin. Microbiol. 42 (2004) 269-275
24. Jones R.N., and Pfaller M.A. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum β-lactamase in Europe. Clin. Microbiol. Infect. 9 (2003) 708-712
25. Nijssen S., Florijn A., Bonten M.J., Schmitz F.J., Verhoef J., and Fluit A.C. β-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int. J. Antimicrob. Agents 24 (2004) 585-591
26. Hanberger H., Diekema D., Fluit A., Jones R.N., Struelens M.J., Spencer R., et al. Surveillance of antibiotic resistance in European ICUs. J. Hosp. Infect. 48 (2001) 161-176
27. Brun-Buisson C., Legrand P., Philippon A., Montravers F., Ansquer M., and Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 2 (1987) 302-306
28. Monnet D.L., Biddle J.W., Edwards J.R., Culver D.H., Tolson J.S., Martone W.J., et al. Evidence of interhospital transmission of extended-spectrum β-lactam-resistant Klebsiella pneumoniae in the USA, 1986 to 1993. Infect. Control Hosp. Epidemiol. 18 (1997) 492-498
29. Pena C., Pujol M., Ricart A., Ardanuy C., Ayats J., Linares J., et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. J. Hosp. Infect. 35 (1997) 9-16
30. Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., and Fishman N.O. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32 (2001) 1162-1171
31. Asensio A., Oliver A., Gonzalez-Diego P., Baquero F., Perez-Diaz J.C., Ros P., et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin. Infect. Dis. 30 (2000) 55-60
32. Wiener J., Quinn J.P., Bradford P.A., Goering R.V., Nathan C., Bush K., et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281 (1999) 517-523
33. Kassis-Chikhani N., Vimont S., Asselat K., Trivalle C., Minassian B., Sengelin C., et al. CTX-M β-lactamase-producing Escherichia coli in long-term care facilities, France. Emerg. Infect. Dis. 10 (2004) 1697-1698
34. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann. Intern. Med. 140 (2004) 26-32
35. Duman M., Abacioglu H., Karaman M., Duman N., and Ozkan H. β-lactam antibiotic resistance in aerobic commensal fecal flora of newborns. Pediatr. Int. 47 (2005) 267-273
36. Bush K. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32 (2001) 1085-1089
37. Kim B.N., Woo J.H., Kim M.N., Ryu J., and Kim Y.S. Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia. J. Hosp. Infect. 52 (2002) 99-106
38. Struelens M., and Byl B. Epidémies en réanimation : identification et prise en charge. In: Carlet J., Dumay M.F., Lucet J.C., and Macrez A. (Eds). Risques infectieux en réanimation (2002), Masson, Paris 79-86
39. Lucet J.C., Chevret S., Decre D., Vanjak D., Macrez A., Bedos J.P., et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin. Infect. Dis. 22 (1996) 430-436
40. Harris A.D., Nemoy L., Johnson J.A., Martin-Carnahan A., Smith D.L., Standiford H., et al. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum β-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect. Control Hosp. Epidemiol. 25 (2004) 105-108
41. Gori A., Espinasse F., Deplano A., Nonhoff C., Nicolas M.H., and Struelens M.J. Comparison of pulsed-field gel electrophoresis and randomly amplified DNA polymorphism analysis for typing extended-spectrum-β-lactamase-producing Klebsiella pneumoniae. J. Clin. Microbiol. 34 (1996) 2448-2453
42. Lucet J.C., Decré D., Fichelle A., Joly-Guillou M.L., Pernet M., Deblangy C., et al. Control of a prolonged outbreack of extended-spectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin. Infect. Dis. 29 (1999) 1411-1418
43. Macrae M.B., Shannon K.P., Rayner D.M., Kaiser A.M., Hoffman P.N., and French G.L. A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure. J. Hosp. Infect. 49 (2001) 183-192
44. Rahal J., Urban C., Horn D., Freeman K., Segal-Maurer S., Maurer J., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280 (1998) 1233-1237
45. Brun-Buisson C., Legrand P., Rauss A., Richard C., Montravers F., Besbes M., et al. Intestinal decontamination for control of nosocomial multiresistant Gram-negative bacilli. Ann. Intern. Med. 110 (1989) 873-881
46. Paterson D.L., Singh N., Rihs J.D., Squier C., Rihs B.L., and Muder R.R. Control of an outbreak of infection due to extended-spectrum β-lactamase-producing Escherichia coli in a liver transplantation unit. Clin. Infect. Dis. 33 (2001) 126-128
47. Lartigue M.F., Poirel L., Decousser J.W., and Nordmann P. Multidrug-resistant Shigella sonnei and Salmonella enterica serotype typhimurium isolates producing CTX-M β-lactamases as causes of community-acquired infection in France. Clin. Infect. Dis. 40 (2005) 1069-1070
48. Pitout J.D., Nordmann P., Laupland K.B., and Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 56 (2005) 52-59
49. Valverde A., Coque T.M., Sanchez-Moreno M.P., Rollan A., Baquero F., and Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J. Clin. Microbiol. 42 (2004) 4769-4775
50. Pallecchi L., Malossi M., Mantella A., Gotuzzo E., Trigoso C., Bartoloni A., et al. Detection of CTX-M-type β-lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. Antimicrob. Agents Chemother. 48 (2004) 4556-4561
51. Rodriguez-Bano J., Navarro M.D., Romero L., Martinez-Martinez L., Muniain M.A., Perea E.J., et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol. 42 (2004) 1089-1094
52. Brinas L., Moreno M.A., Zarazaga M., Porrero C., Saenz Y., Garcia M., et al. Detection of CMY-2, CTX-M-14, and SHV-12 β-lactamases in Escherichia coli fecal-sample isolates from healthy chickens. Antimicrob. Agents Chemother. 47 (2003) 2056-2058
53. Brinas L., Moreno M.A., Teshager T., Saenz Y., Porrero M.C., Dominguez L., et al. Monitoring and characterization of extended-spectrum β-lactamases in Escherichia coli strains from healthy and sick animals in Spain in 2003. Antimicrob. Agents Chemother. 49 (2005) 1262-1264
54. Weill F.X., Lailler R., Praud K., Kerouanton A., Fabre L., Brisabois A., et al. Emergence of extended-spectrum-β-lactamase (CTX-M-9)-producing multiresistant strains of Salmonella enterica serotype Virchow in poultry and humans in France. J. Clin. Microbiol. 42 (2004) 5767-5773
55. Jones R.N., and Pfaller M.A. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum β-lactamase in Europe. Clin. Microbiol. Infect. 9 (2003) 708-712
56. Jones R.N., Biedenbach D.J., and Gales A.C. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int. J. Antimicrob. Agents 21 (2003) 1-7
57. Martinez-Martinez L., Hernandez-Alles S., Alberti S., Tomas J.M., Benedi V.J., and Jacoby G.A. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob. Agents Chemother. 40 (1996) 342-348
58. Paterson D.L., Mulazimoglu L., Casellas J.M., Ko W.C., Goossens H., Von Gottberg A., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis. 30 (2000) 473-478
59. Nordmann P., and Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J. Antimicrob. Chemother. 56 (2005) 463-469
60. Endimiani A., Luzzaro F., Perilli M., Lombardi G., Coli A., Tamborini A., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin. Infect. Dis. 38 (2004) 243-251
61. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis. 39 (2004) 31-37
62. Goethaert K., Van Looveren M., Lammens C., Jansens H., Baraniak A., Gniadkowski M., et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin. Microbiol. Infect. 12 (2006) 56-62
63. Elkhaili H., Kamili N., Linger L., Leveque D., Pompei D., Monteil H., et al. In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum β-lactamase. Chemotherapy 43 (1997) 245-253
64. Zanetti G., Bally F., Greub G., Garbino J., Kinge T., Lew D., et al. Cefepime vs imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob. Agents Chemother. 47 (2003) 3442-3447
65. Paterson D.L., Ko W.C., Von Gottberg A., Casellas J.M., Mulazimoglu L., Klugman K.P., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39 (2001) 2206-2212
66. Hyle E.P., Lipworth A.D., Zaoutis T.E., Nachamkin I., Bilker W.B., and Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing enterobacteriaceae: variability by site of infection. Arch. Intern. Med. 165 (2005) 1375-1380
67. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48 (2004) 4574-4581
68. MacKenzie F.M., Forbes K.J., Dorai-John T., Amyes S.G., and Gould I.M. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 350 (1997) 783
69. De Gheldre Y., Maes N., Rost F., De Ryck R., Clevenbergh P., Vincent J.L., et al. Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance. J. Clin. Microbiol. 35 (1997) 152-160
70. Bornet C., Davin-Regli A., Bosi C., Pages J.M., and Bollet C. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J. Clin. Microbiol. 38 (2000) 1048-1052
71. Naas T., Nordmann P., Vedel G., and Poyart C. Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob. Agents Chemother. 49 (2005) 4423-4424
72. Hong T., Moland E.S., Abdalhamid B., Hanson N.D., Wang J., Sloan C., et al. Escherichia coli: development of carbapenem resistance during therapy. Clin. Infect. Dis. 40 (2005) e84-e86
73. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165 (2005) 1430-1435